Patents Assigned to Satiogen Pharmaceuticals, Inc.
  • Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
    Patent number: 11260053
    Abstract: Provided herein are methods of utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents for the treatment of obesity, diabetes, and inflammatory gastrointestinal conditions.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: March 1, 2022
    Assignee: SATIOGEN PHARMACEUTICALS, INC.
    Inventors: Bronislava Gedulin, Andrew A. Young, Howard E. Greene
  • Bile acid recycling inhibitors for treatment of obesity and diabetes
    Patent number: 10555950
    Abstract: Provided herein are methods of utilizing bile acid transport inhibitors for the treatment of obesity and diabetes.
    Type: Grant
    Filed: April 12, 2016
    Date of Patent: February 11, 2020
    Assignee: SATIOGEN PHARMACEUTICALS, INC.
    Inventors: Andrew A. Young, Bronislava Gedulin, Howard E. Greene
  • Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
    Patent number: 10251880
    Abstract: Provided herein are methods of utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents for the treatment of obesity, diabetes, and inflammatory gastrointestinal conditions.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: April 9, 2019
    Assignee: SATIOGEN PHARMACEUTICALS, INC.
    Inventors: Bronislava Gedulin, Andrew A. Young, Howard E. Greene
  • Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
    Patent number: 10188646
    Abstract: Provided herein are methods of utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents for the treatment of obesity, diabetes, and inflammatory gastrointestinal conditions.
    Type: Grant
    Filed: February 22, 2012
    Date of Patent: January 29, 2019
    Assignee: SATIOGEN PHARMACEUTICALS, INC.
    Inventors: Bronislava Gedulin, Andrew A. Young, Howard E. Greene
  • Methods of treating diabetes or obesity using bile acids, bile salts, and mimics thereof
    Patent number: 10028952
    Abstract: Provided herein are methods and compositions for treating metabolic diseases and conditions associated with metabolic diseases.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: July 24, 2018
    Assignee: SATIOGEN PHARMACEUTICALS, INC
    Inventors: Andrew A. Young, Bronislava Gedulin, Howard E. Greene
  • Methods of treating diabetes or obesity using bile acids, bile salts, and mimics thereof
    Patent number: 9345715
    Abstract: Provided herein are methods and compositions for treating metabolic diseases and conditions associated with metabolic diseases.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: May 24, 2016
    Assignee: SATIOGEN PHARMACEUTICALS, INC.
    Inventors: Andrew A. Young, Bronislava Gedulin, Howard E. Greene
  • Bile acid recycling inhibitors for treatment of obesity and diabetes
    Patent number: 9339480
    Abstract: Provided herein are methods of utilizing bile acid transport inhibitors for the treatment of obesity and diabetes.
    Type: Grant
    Filed: November 23, 2009
    Date of Patent: May 17, 2016
    Assignee: SATIOGEN PHARMACEUTICALS, INC.
    Inventors: Andrew A. Young, Bronislava Gedulin, Howard E. Greene
  • Compositions Containing Satiogens and Methods of Use
    Publication number: 20130190281
    Abstract: Provided herein are methods and compositions for treating metabolic diseases and conditions associated with metabolic diseases.
    Type: Application
    Filed: November 9, 2012
    Publication date: July 25, 2013
    Applicant: Satiogen Pharmaceuticals, Inc.
    Inventor: Satiogen Pharmaceuticals, Inc.
  • Methods and Apparatus for Treating Obesity and Diabetes
    Publication number: 20130090590
    Abstract: Provided herein are methods and shunt devices for treating diabetes and obesity. Methods and shunt devices promote stimulation of secretion of intestinal L-cells and other enteroendocrine cell types. Enteroendocrine secretion is stimulated directly or indirectly by shunting bile and/or pancreatic secretion to segments of the gut more distal than would normally occur. The shunt device may be a flexible catheter that is impervious to such secretions, with a proximal end draining the pancreatic/bile duct, and a distal end residing distally within the lumen of the small or large intestine. The shunt may be inserted with minimally invasive techniques, such as by endoscopy or laparoscopy.
    Type: Application
    Filed: November 29, 2012
    Publication date: April 11, 2013
    Applicant: Satiogen Pharmaceuticals, Inc.
    Inventor: Satiogen Pharmaceuticals, Inc.
  • BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS
    Publication number: 20130059807
    Abstract: Provided herein are methods of utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents for the treatment of obesity, diabetes, and inflammatory gastrointestinal conditions.
    Type: Application
    Filed: February 22, 2012
    Publication date: March 7, 2013
    Applicant: Satiogen Pharmaceuticals, Inc.
    Inventors: Bronislava Gedulin, Andrew A. Young, Howard E. Greene
  • Biliary/pancreatic shunt device and method for treatment of metabolic and other diseases
    Patent number: 8366650
    Abstract: Provided is a shunt device that promotes stimulation of secretion of intestinal L-cells and other enteroendocrine cell types. Enteroendocrine secretion is stimulated directly or indirectly by shunting bile and/or pancreatic secretion to segments of the gut more distal than would normally occur The shunt device may be a flexible catheter that is impervious to such secretions, with a proximal end draining the pancreatic/bile duct, and a distal end residing distally within the lumen of the small or large intestine. The shunt may be inserted with minimally invasive techniques, such as by endoscopy.
    Type: Grant
    Filed: October 24, 2006
    Date of Patent: February 5, 2013
    Assignee: Satiogen Pharmaceuticals, Inc.
    Inventor: Andrew Young
  • Methods of treating diabetes and/or obesity using an enteroendocrine peptide secretion enhancing agent
    Patent number: 8318663
    Abstract: Provided herein are methods and compositions for treating metabolic diseases and conditions associated with metabolic diseases.
    Type: Grant
    Filed: November 23, 2009
    Date of Patent: November 27, 2012
    Assignee: Satiogen Pharmaceuticals, Inc.
    Inventors: Andrew A. Young, Bronislava Gedulin, Howard E. Greene
  • BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF OBESITY AND DIABETES
    Publication number: 20120157399
    Abstract: Provided herein are methods of utilizing bile acid transport inhibitors for the treatment of obesity and diabetes.
    Type: Application
    Filed: February 22, 2012
    Publication date: June 21, 2012
    Applicant: Satiogen Pharmaceuticals, Inc.
    Inventors: Andrew A. Young, Bronislava Gedulin, Howard E. Greene
  • BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS
    Publication number: 20110294767
    Abstract: Provided herein are methods of utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents for the treatment of obesity, diabetes, and inflammatory gastrointestinal conditions.
    Type: Application
    Filed: May 26, 2011
    Publication date: December 1, 2011
    Applicant: Satiogen Pharmaceuticals, Inc.
    Inventors: Bronislava Gedulin, Andrew A. Young, Howard E. Greene
  • Treatment of Obesity or Diabetes with Bile Acid Sequestrants
    Publication number: 20110152204
    Abstract: Provided herein are methods of treating obesity and diabetes with labile bile acid sequestrants. An effective amount of a labile bile acid sequestrant may be orally administered to an obese or diabetic individual. A labile bile acid sequestrant provided herein may have a low affinity in the colon or rectum of a human for at least one bile acid or bile acid mimic that stimulates L-cells. A labile bile acid sequestrant may be a non-systemic labile bile acid sequestrant.
    Type: Application
    Filed: December 15, 2010
    Publication date: June 23, 2011
    Applicant: Satiogen Pharmaceuticals, Inc.
    Inventors: Bronislava GEDULIN, Howard E. Greene, JR.
  • COMPOSITIONS CONTAINING SATIOGENS AND METHODS OF USE
    Publication number: 20100130426
    Abstract: Provided herein are methods and compositions for treating metabolic diseases and conditions associated with metabolic diseases.
    Type: Application
    Filed: November 23, 2009
    Publication date: May 27, 2010
    Applicant: SATIOGEN PHARMACEUTICALS, INC.
    Inventors: Andrew A. YOUNG, Bronislava GEDULIN, Howard E. GREENE
  • BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF OBESITY AND DIABETES
    Publication number: 20100130472
    Abstract: Provided herein are methods of utilizing bile acid transport inhibitors for the treatment of obesity and diabetes.
    Type: Application
    Filed: November 23, 2009
    Publication date: May 27, 2010
    Applicant: SATIOGEN PHARMACEUTICALS, INC.
    Inventors: Andrew A. YOUNG, Bronislava GEDULIN, Howard E. GREENE